The first results of the application of the rectal suppositories «Bioprost» for the treatment of patients with non-specific chronic prostatitis

М.А. М ironov

N.N. Burdenko Regional Clinical Hospital, Penza

Chronic prostatitis remains the most wide-spread inflammatory disease with men, well-known to every urologist. In average up to 50 % of men eventually develop it and half of them have clinical symptoms requiring a consultation with the doctor and treatment.

A big number of methods of treatment as well as medications prescribed for chronic prostatitis testify for its pluricausal nature and variability of pathogenic mechanisms. The provided therapy often has an empirical character.

Consequently, the treatment can last for several months which leads to the increased pharmacological load, higher cost of treatment, the development of complications and side effects of the therapy. This resulted in the increased use of phytopharmaceutical medicines in various dosage forms, in particular in the form of rectal suppositories.

The new medicine Bioprost ® is developed and manufactured by ZAO Intelpharm , Nizhny Novgorod in the form of rectal suppositories and contains 0,5 g of pumpkin seed oil and 0,1 g of thymic acid. Pumpkin seed oil contains a large amount of unsaturated fat acids, antioxidants and microelements which are effective means for the jugulation of the prostate inflammation. Thymic acid has an explicit anti-inflammatory effect. Rectal administration is preferable because it provides delivery of the medicine to blood passing the liver barrier which allows a quick therapeutic effect and excludes inactivation of the medicine by the digestive juice and liver. It leads to a higher concentration of the substance in the secretion and tissue of the prostate gland.

The clinical trial consisted of two groups of 10 people of similar age, having similar intensity of symptoms and changes of laboratory parameters. All the patients had non-specific chronic prostatitis in the subacute phase, in the torpid phase or in the latent phase which was confirmed by the USI, digital rectal examination, clinical and laboratory data, (the three-glass urine test, the prostatic secretion or ejaculate analysis, general urine analysis, a bacteriological study of the prostatic secretion), uroflowmetry, studies of the symptoms indexes according to the SES-CP (summary evaluation of symptoms of chronic prostatitis) questionnaires. Patients of both groups received “Eleflox” ( Levofloxacin ) 500 mg 1 time a day for 2 weeks, standard physiotherapy (Magnetic and Laser Therapy, Extremely High Frequency Therapy, Amplipulse Therapy etc.), the prostate massage; patients with dysuria received a-adrenoblockers (Setegis 2-5 mg) 1 time a day. Patients from the first group were additionally given Bioprost ® - 1 suppository 2 times a day.

The efficacy evaluation was performed according to the following criteria:

Excellent – disappearance of all the symptoms of the disease, normalizing of the laboratory and objective data;

Good – regression, involution of the symptoms, positive dynamics of the objective data and the laboratory and instrumental investigations;

Satisfactory – moderate regression, involution of the symptoms, positive dynamics of the objective data and the laboratory and instrumental investigations;

No effect

Negative effect

After the treatment including “Eleflox” ( Levofloxacin ), the check bacteriological study showed the absence of the agents with all the patients.

The check study of the prostatic secretion after the therapy showed decrease in leucocytes and the increase in the lecithin grains with 9 patients and no dynamics concerning the prostatic secretion with one patient from the first group. As far as the second group, 4 patients had no dynamics and six showed positive dynamics.

The analysis of the SES-CP (summary evaluation of symptoms of chronic prostatitis) questionnaires showed the drop of the average ball down to 10.9 + 2.7 in the first group and down to 16.7 + 3.3 in the second group.

The efficacy evaluation gave the following results:

The safety and tolerance assessment didn’t show a single topical change of the skin or the mucous coating, negative dynamics in the blood and urine analyses, nor any ill health. None of the participants refused the treatment because of undesirable side effects.

As the result of the trial we must note that the use of Bioprost ® with patients with non-specific chronic prostatitis is pathogenetically reasonable, expedient, safe and effective in the latent and subacute phase. The treatment resulted in reduction of the inflammatory reaction of the prostatic tissue, quick jugulation of the inflammation, improvement of objective and subjective symptoms. The medicine doesn’t cause any undesirable consequences, is well tolerable, convenient and user-friendly. The medicine can be recommended for doctors who deal with patients having non-specific chronic prostatitis as well as for patients as a prevention measure due to its safety.